Adibelivir (parenteral)
Herpes Simplex Encephalitis (HSE)
Pre-clinical/Phase 1Active (Licensed to Alfasigma)
Key Facts
Indication
Herpes Simplex Encephalitis (HSE)
Phase
Pre-clinical/Phase 1
Status
Active (Licensed to Alfasigma)
Company
About Innovative Molecules
Innovative Molecules is a private, clinical-stage biotech focused on developing novel antiviral therapies for herpes simplex virus (HSV) infections. Its lead program, IM-250 (adibelivir), an oral helicase-primase inhibitor, has completed Phase 1 and advanced to Phase 2 trials, demonstrating a targeted mechanism to control recurrent disease and latent virus. The company has secured significant Series A funding and established a strategic partnership with Alfasigma for a parenteral formulation, positioning it to address a substantial unmet medical need in a market dominated by older, less effective nucleoside analogues.
View full company profile